FOLD Amicus Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

FOLD [NASD]

Amicus Therapeutics, Inc.

Healthcare | Biotechnology | USA

financial highlights | statements

Index	-	P/E	-	EPS (ttm)	-1.89	Insider Own	0.40%	Shs Outstand	193.40M	Perf Week	1.51%
Market Cap	2.08B	Forward P/E	-	EPS next Y	-0.87	Insider Trans	479.04%	Shs Float	187.96M	Perf Month	-12.53%
Income	-342.80M	PEG	-	EPS next Q	-0.29	Inst Own	-	Short Float	14.03%	Perf Quarter	-18.31%
Sales	73.30M	P/S	28.36	EPS this Y	-25.60%	Inst Trans	-0.13%	Short Ratio	9.35	Perf Half Y	-31.75%
Book/sh	2.17	P/B	4.95	EPS next Y	34.60%	ROA	-43.00%	Target Price	18.50	Perf Year	-20.25%
Cash/sh	2.92	P/C	3.68	EPS next 5Y	-	ROE	-73.60%	52W Range	9.99 - 17.62	Perf YTD	-25.30%
Dividend	-	P/FCF	-	EPS past 5Y	-11.80%	ROI	-54.00%	52W High	-38.99%	Beta	1.37
Dividend %	-	Quick Ratio	9.00	Sales past 5Y	14.90%	Gross Margin	82.70%	52W Low	7.61%	ATR	0.75
Employees	325	Current Ratio	9.10	Sales Q/Q	89.00%	Oper. Margin	-	RSI (14)	45.01	Volatility	7.29% 7.32%
Optionable	Yes	Debt/Eq	0.78	EPS Q/Q	-21.20%	Profit Margin	-	Rel Volume	1.52	Prev Close	10.40
Shortable	Yes	LT Debt/Eq	0.78	Earnings	Nov 05 BMO	Payout	-	Avg Volume	2.82M	Price	10.75
Recom	2.00	SMA20	-3.33%	SMA50	-9.33%	SMA200	-24.03%	Volume	4,294,590	Change	3.37%

Oct-29-18

Initiated

Citigroup

Neutral

$12

Aug-17-18

Downgrade

Chardan Capital Markets

Buy → Neutral

$18 → $15

Oct-06-17

Resumed

Goldman

Neutral

Sep-13-17

Reiterated

Chardan Capital Markets

Buy

$17.50 → $16.50

Aug-10-17

Reiterated

Chardan Capital Markets

Buy

$12.50 → $17.50

Jan-24-17

Upgrade

Robert W. Baird

Neutral → Outperform

$7 → $10

May-18-16

Initiated

BofA/Merrill

Buy

$10

Apr-14-16

Initiated

Robert W. Baird

Neutral

Apr-12-16

Reiterated

Chardan Capital Markets

Buy

$10 → $15

Sep-16-15

Downgrade

Chardan Capital Markets

Buy → Neutral

$17

Jun-16-15

Reiterated

Chardan Capital Markets

Buy

$14 → $17.50

May-29-15

Initiated

Chardan Capital Markets

Buy

$14

Dec-20-12

Reiterated

Canaccord Genuity

Buy

$11 → $6

Dec-20-12

Downgrade

Capstone Investments

Buy → Hold

Nov-01-12

Initiated

Capstone Investments

Buy

Apr-06-10

Initiated

Canaccord Adams

Buy

Mar-31-10

Initiated

Leerink Swann

Mkt Perform

Oct-05-09

Downgrade

Wedbush Morgan

Outperform → Underperform

$17 → $3.50

Mar-20-09

Initiated

Wedbush Morgan

Buy

$17

Feb-27-09

Reiterated

Lazard Capital

Buy

$18 → $15

Nov-14-18 06:55AM	Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen ACCESSWIRE -5.01%
Nov-12-18 07:00AM	Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference GlobeNewswire
Nov-05-18 01:25PM	Edited Transcript of FOLD earnings conference call or presentation 5-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
08:45AM	Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:42AM	Amicus Therapeutics: 3Q Earnings Snapshot Associated Press
07:00AM	Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates GlobeNewswire
Oct-29-18 08:00AM	Today's Research Reports on Trending Tickers: Amicus Therapeutics and Geron ACCESSWIRE
07:00AM	Amicus Therapeutics to Announce Third Quarter 2018 Financial Results on November 5, 2018 GlobeNewswire
Oct-25-18 09:25AM	Recent Analysis Shows PennyMac Mortgage Investment Trust, Amicus Therapeutics, Children's Place, PLDT, NanoString Technologies, and Worthington Industries Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +5.08%
Oct-22-18 01:56PM	5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout InvestorPlace
Oct-15-18 08:00AM	Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Amicus Therapeutics ACCESSWIRE
Oct-11-18 07:00AM	Amicus Therapeutics to Host Analyst Day 2018 Today in New York City GlobeNewswire
Oct-08-18 07:00AM	Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies GlobeNewswire
Oct-05-18 07:00AM	Amicus Therapeutics Announces Positive 18-Month Data in Pompe Disease Phase 1/2 Study at 23rd International Annual Congress of the World Muscle Society GlobeNewswire
Oct-04-18 11:08AM	Amicus Therapeutics is looking to find a cure for rare diseases Yahoo Finance Video
08:44AM	Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 6.7% Zacks
Oct-02-18 07:00AM	Amicus Therapeutics Announces Presentation and Poster at the 23rd International Congress of the World Muscle Society GlobeNewswire
Sep-27-18 08:00AM	Today's Research Reports on Trending Tickers: Amarin and Amicus Therapeutics ACCESSWIRE
Sep-26-18 07:00AM	Amicus Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire
Sep-25-18 07:55AM	Report: Exploring Fundamental Drivers Behind Ocean Power Technologies, Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, Fanhua, and Parsley Energy New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Sep-24-18 02:21PM	Tavistock Restaurants to open new Lake Nona pizza and brew pub American City Business Journals
Sep-20-18 11:27AM	Why Amicus Therapeutics Is Up 10% Today Motley Fool +6.86%
07:41AM	[$$] Amicus to Acquire Gene Therapy Company Celenex The Wall Street Journal
06:00AM	Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders GlobeNewswire
Sep-19-18 02:38PM	7 Biotech Stocks to Buy Now InvestorPlace
Sep-14-18 02:36PM	See future biotech facility slated for Lake Nona (PHOTOS) American City Business Journals
Sep-13-18 05:26PM	Is Amicus Therapeutics choosing Orlando for high-wage biotech jobs site? Sure looks like it American City Business Journals
Sep-11-18 07:00AM	Amicus Therapeutics Announces Board Appointments GlobeNewswire
Sep-10-18 08:00AM	Today's Research Reports on Trending Tickers: Amicus Therapeutics and Intercept Pharmaceuticals ACCESSWIRE
07:00AM	Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease GlobeNewswire
Sep-06-18 04:05PM	Eateries, entertainment slated for $780M Lake Nona Town Center's 'Boxi Park' American City Business Journals -6.12%
Aug-31-18 01:19PM	Global biotech firm may add to growing Lake Nona presence American City Business Journals
07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2018 GlobeNewswire
Aug-21-18 11:05AM	Lake Nona may get global biotech firm to build facility, create 300+ high-wage jobs American City Business Journals
Aug-13-18 01:26PM	The Week Ahead: Nvidia, Retailer Earnings In Focus Benzinga -6.78%
10:16AM	Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold Zacks
09:04AM	Amicus sets $315,000 price for new Fabry disease treatment Reuters
08:28AM	Amicus sets $315,000 price for new Fabry disease treatment Reuters
Aug-12-18 04:52PM	The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs Benzinga
Aug-10-18 05:50PM	Amicus Therapeutics receives U.S. approval for Fabry disease drug Reuters
04:05PM	FDA Approves Galafold (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease GlobeNewswire
Aug-07-18 09:20AM	Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates Zacks +7.28%
08:17AM	Amicus Therapeutics: 2Q Earnings Snapshot Associated Press
07:00AM	Amicus Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Updates GlobeNewswire
06:30AM	Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-18 03:35PM	Q2 Earnings Outlook For Amicus Therapeutics Benzinga
Jul-31-18 07:40AM	Report: Developing Opportunities within Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, State Street, Alphabet, and VBI Vaccines Future Expectations, Projections Moving into 2018 GlobeNewswire
07:30AM	Amicus Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
Jul-30-18 08:00AM	Research Report Identifies General Dynamics, General Motors, Amicus Therapeutics, Drive Shack, Zoe's Kitchen, and Vishay Intertechnology with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:00AM	Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks ACCESSWIRE
Jun-29-18 07:25AM	Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks ACCESSWIRE
Jun-27-18 11:32AM	All You Need To Know About Amicus Therapeutics Incs (NASDAQ:FOLD) Financial Health Simply Wall St.
08:14AM	Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading Benzinga
08:00AM	Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics ACCESSWIRE
Jun-26-18 04:05PM	Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease GlobeNewswire
Jun-08-18 07:00AM	Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors GlobeNewswire
Jun-01-18 07:00AM	Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference GlobeNewswire
May-30-18 12:00AM	Amicus Therapeutics Launches Galafold® (Migalastat) for Fabry Disease in Japan GlobeNewswire +7.93%
May-25-18 08:30AM	Today's Research Reports on Trending Tickers: Amicus Therapeutics and Insmed ACCESSWIRE
May-24-18 01:55PM	Netflix, McKesson, Amicus Therapeutics, Microsoft & Micro... CNBC Videos +5.08%
May-23-18 07:00AM	Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks ACCESSWIRE
May-16-18 08:20AM	Today's Research Reports on Trending Tickers: Puma Biotechnology and Amicus Therapeutics ACCESSWIRE +9.18%
May-14-18 12:39PM	Edited Transcript of FOLD earnings conference call or presentation 8-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-09-18 07:30AM	Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
May-08-18 11:47AM	When Can We Expect A Profit From Amicus Therapeutics Inc (NASDAQ:FOLD)? Simply Wall St. -6.92%
08:57AM	Amicus Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM	Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates GlobeNewswire
Apr-26-18 07:30AM	Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018 GlobeNewswire
Apr-20-18 08:37AM	Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options Zacks
Apr-17-18 07:30AM	Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day GlobeNewswire
Apr-16-18 07:55AM	Report: Developing Opportunities within Amicus Therapeutics, Rite Aid, Navient, ProPetro Holding, Pfizer, and Sysco Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-30-18 08:00AM	[$$] 3 Biotech Stocks a Pro Is Buying Now Barrons.com
Mar-22-18 09:30PM	Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan GlobeNewswire
Mar-09-18 08:15AM	Research Report Identifies Rayonier, Gannett Co., CBIZ, Amicus Therapeutics, Iamgold, and Urban Outfitters with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-05-18 07:30AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2018 GlobeNewswire
Mar-01-18 08:30AM	Todays Research Reports on Trending Tickers: Gilead Sciences and Amicus Therapeutics ACCESSWIRE
12:16AM	Edited Transcript of FOLD earnings conference call or presentation 28-Feb-18 1:30pm GMT Thomson Reuters StreetEvents
Feb-28-18 07:00AM	Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates GlobeNewswire -9.11%
06:30AM	Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-27-18 04:01PM	Amicus Therapeutics Launches Healing Beyond Disease Initiatives to Change Peoples Lives Living with Rare Diseases GlobeNewswire
Feb-25-18 03:50PM	The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
Feb-21-18 04:30PM	Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock GlobeNewswire
07:30AM	Amicus Therapeutics to Announce Full-Year 2017 Financial Results on February 28, 2018 GlobeNewswire
Feb-15-18 07:00PM	Amicus Therapeutics Prices Underwritten Offering of Common Stock GlobeNewswire
Feb-14-18 04:01PM	Amicus Therapeutics Announces Public Offering of Common Stock GlobeNewswire +7.25%
07:30AM	Blog Exposure - FDA Accepts Amicus Therapeutics NDA for Migalastat for Treatment of Fabry Disease ACCESSWIRE
Feb-13-18 04:01PM	Amicus Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference GlobeNewswire
Feb-12-18 07:30AM	U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease GlobeNewswire
Feb-07-18 04:01PM	Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium GlobeNewswire
Jan-31-18 11:02AM	Best Growth Stock in January Simply Wall St.
Jan-30-18 08:20AM	Todays Research Reports on Trending Tickers: Geron Corporation and Amicus Therapeutics, Inc. ACCESSWIRE
Jan-29-18 07:30AM	Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold (migalastat) for Fabry Disease in Canada GlobeNewswire
Jan-27-18 02:00PM	2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs TheStreet.com
Jan-26-18 01:14AM	[$$] The Tax Law, Just One Month Old, Is Roaring Through U.S. Companies The Wall Street Journal
Jan-22-18 04:01PM	Amicus Therapeutics Announces Presentations and Posters at 14th Annual WORLDSymposium 2018 GlobeNewswire
Jan-17-18 04:01PM	Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in Spain GlobeNewswire
Jan-11-18 08:56AM	Amicus Therapeutics (FOLD) Surges: Stock Moves 9.2% Higher Zacks
Jan-10-18 01:59PM	Lincoln National, Sears, Hasbro, Steris & Amicus Therapeu... CNBC Videos +9.15%
Jan-08-18 08:10AM	Todays Research Reports on Trending Tickers: Amicus Therapeutics, Inc. and Synergy Pharmaceuticals, Inc. ACCESSWIRE -6.37%
07:30AM	Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance GlobeNewswire

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Baird William D III	Chief Financial Officer	Oct 15	Option Exercise	2.45	10,000	24,500	127,622	Oct 17 06:28 PM
Baird William D III	Chief Financial Officer	Oct 15	Sale	12.23	10,000	122,275	117,622	Oct 17 06:28 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Oct 03	Buy	12.69	30,000	380,700	20,724,424	Oct 05 08:36 AM
PERCEPTIVE ADVISORS LLC	10% Owner	Sep 24	Buy	12.45	20,000	249,000	20,694,424	Oct 05 08:36 AM
PERCEPTIVE ADVISORS LLC	10% Owner	Sep 21	Buy	12.53	50,000	626,500	20,674,424	Sep 25 08:30 AM
PERCEPTIVE ADVISORS LLC	10% Owner	Sep 13	Buy	11.74	100,000	1,174,000	20,624,424	Sep 17 08:22 AM
PERCEPTIVE ADVISORS LLC	10% Owner	Sep 12	Buy	12.00	500,000	6,001,500	20,524,424	Sep 14 08:30 AM
Andrews Kurt J.	SVP, Human Resources	Jul 02	Option Exercise	6.13	5,000	30,650	40,469	Jul 05 04:25 PM
Baird William D III	Chief Financial Officer	Jul 02	Option Exercise	2.45	10,000	24,500	117,622	Jul 05 04:27 PM
Andrews Kurt J.	SVP, Human Resources	Jul 02	Sale	15.63	5,000	78,166	35,469	Jul 05 04:25 PM
Baird William D III	Chief Financial Officer	Jul 02	Sale	15.63	10,000	156,292	107,622	Jul 05 04:27 PM
Do Hung	Chief Science Officer	Jun 01	Sale	16.72	25,000	418,000	396,771	Jun 04 05:18 PM
MCGLYNN MARGARET G	Director	May 16	Option Exercise	3.32	10,000	33,200	25,814	May 18 06:07 PM
Do Hung	Chief Science Officer	May 16	Sale	15.00	25,000	375,000	421,771	May 16 06:22 PM
MCGLYNN MARGARET G	Director	May 16	Sale	16.00	10,000	160,000	15,814	May 18 06:07 PM
Barth Jay	Chief Medical Officer	May 14	Option Exercise	2.29	5,000	11,450	90,409	May 15 07:37 PM
Barth Jay	Chief Medical Officer	May 14	Sale	14.04	5,000	70,223	85,409	May 15 07:37 PM
Do Hung	Chief Science Officer	Apr 17	Sale	15.00	50,000	750,000	446,771	Apr 19 06:03 PM
RAAB MICHAEL	Director	Apr 16	Option Exercise	10.53	5,000	52,650	10,814	Apr 18 06:03 PM
RAAB MICHAEL	Director	Apr 16	Sale	14.41	5,000	72,058	5,814	Apr 18 06:03 PM
Barth Jay	Chief Medical Officer	Apr 12	Option Exercise	2.29	5,000	11,450	90,409	Apr 16 05:31 PM
Barth Jay	Chief Medical Officer	Apr 12	Sale	14.72	5,000	73,602	85,409	Apr 16 05:31 PM
Baird William D III	Chief Financial Officer	Apr 02	Option Exercise	2.45	10,000	24,500	127,662	Apr 04 05:38 PM
Andrews Kurt J.	SVP, Human Resources	Apr 02	Option Exercise	6.13	5,000	30,650	45,469	Apr 04 05:39 PM
Andrews Kurt J.	SVP, Human Resources	Apr 02	Sale	14.27	5,000	71,343	40,469	Apr 04 05:39 PM
Baird William D III	Chief Financial Officer	Apr 02	Sale	14.26	10,000	142,648	117,622	Apr 04 05:38 PM
Barth Jay	Chief Medical Officer	Mar 12	Option Exercise	2.29	5,000	11,450	90,409	Mar 13 06:41 PM
Barth Jay	Chief Medical Officer	Mar 12	Sale	15.05	5,000	75,253	85,409	Mar 13 06:41 PM
Quimi Daphne	SVP, Finance	Mar 09	Option Exercise	5.96	8,750	52,150	73,082	Mar 12 06:04 PM
Quimi Daphne	SVP, Finance	Mar 09	Sale	15.00	8,750	131,250	64,332	Mar 12 06:04 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Mar 05	Buy	13.56	335,827	4,553,814	18,424,424	Mar 07 05:27 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Mar 02	Buy	13.90	100,000	1,389,500	18,088,597	Mar 06 04:22 PM
Quimi Daphne	SVP, Finance	Mar 01	Option Exercise	4.16	8,149	33,900	72,481	Mar 05 05:55 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Mar 01	Buy	13.69	100,000	1,369,000	17,988,597	Mar 05 04:37 PM
Quimi Daphne	SVP, Finance	Mar 01	Sale	14.06	8,149	114,537	64,332	Mar 05 05:55 PM
Barth Jay	Chief Medical Officer	Jan 23	Option Exercise	2.29	20,000	45,800	105,409	Jan 25 04:16 PM
Barth Jay	Chief Medical Officer	Jan 23	Sale	16.80	20,000	336,000	85,409	Jan 25 04:16 PM
Campbell Bradley L	Chief Operating Officer	Jan 22	Option Exercise	10.21	32,500	331,825	186,600	Jan 24 05:59 PM
Campbell Bradley L	Chief Operating Officer	Jan 22	Sale	15.92	32,500	517,371	154,100	Jan 24 05:59 PM
HAYDEN DONALD J JR	Director	Jan 02	Option Exercise	15.00	20,000	300,002	25,814	Jan 04 05:08 PM
Quimi Daphne	SVP, Finance	Jan 02	Option Exercise	14.72	8,000	117,723	62,676	Jan 04 05:10 PM
Barth Jay	Chief Medical Officer	Jan 02	Option Exercise	14.71	5,000	73,559	69,184	Jan 04 05:12 PM
Baird William D III	Chief Financial Officer	Jan 02	Option Exercise	14.72	10,000	147,181	105,121	Jan 04 05:11 PM
RAAB MICHAEL	Director	Jan 02	Option Exercise	15.00	9,366	140,490	15,180	Jan 04 05:14 PM
Andrews Kurt J.	SVP, Human Resources	Jan 02	Option Exercise	14.72	10,000	147,191	44,737	Jan 04 05:13 PM
Andrews Kurt J.	SVP, Human Resources	Jan 02	Sale	14.72	10,000	147,191	34,737	Jan 04 05:13 PM
RAAB MICHAEL	Director	Jan 02	Sale	15.00	9,366	140,490	5,814	Jan 04 05:14 PM
Baird William D III	Chief Financial Officer	Jan 02	Sale	14.72	10,000	147,181	95,121	Jan 04 05:11 PM
Barth Jay	Chief Medical Officer	Jan 02	Sale	14.71	5,000	73,559	64,184	Jan 04 05:12 PM
Quimi Daphne	SVP, Finance	Jan 02	Sale	14.72	8,000	117,723	54,676	Jan 04 05:10 PM
HAYDEN DONALD J JR	Director	Jan 02	Sale	15.00	20,000	300,002	5,814	Jan 04 05:08 PM
Crowley John F	Chairman & CEO	Dec 29	Option Exercise	14.75	5,920	87,320	333,921	Jan 02 06:00 PM
Crowley John F	Chairman & CEO	Dec 29	Sale	14.75	5,920	87,320	328,001	Jan 02 06:00 PM
Crowley John F	Chairman & CEO	Dec 28	Option Exercise	14.75	13,050	192,497	341,051	Jan 02 06:00 PM
Crowley John F	Chairman & CEO	Dec 28	Sale	14.75	13,050	192,497	328,001	Jan 02 06:00 PM
Crowley John F	Chairman & CEO	Dec 21	Option Exercise	13.51	506	6,836	358,507	Dec 21 05:19 PM
Crowley John F	Chairman & CEO	Dec 21	Sale	13.51	506	6,836	328,001	Dec 21 05:19 PM
Crowley John F	Chairman & CEO	Dec 20	Option Exercise	13.51	65,075	878,929	393,076	Dec 21 05:19 PM
Crowley John F	Chairman & CEO	Dec 20	Sale	13.51	65,075	878,929	328,001	Dec 21 05:19 PM
Crowley John F	Chairman & CEO	Dec 11	Option Exercise	13.52	12,206	164,973	340,207	Dec 13 05:13 PM
Crowley John F	Chairman & CEO	Dec 11	Sale	13.52	12,206	164,973	328,001	Dec 13 05:13 PM
Crowley John F	Chairman & CEO	Dec 04	Option Exercise	13.61	47,213	642,734	375,214	Dec 06 05:46 PM
Crowley John F	Chairman & CEO	Dec 04	Sale	13.61	47,213	642,734	328,001	Dec 06 05:46 PM
Barth Jay	Chief Medical Officer	Dec 01	Option Exercise	13.59	5,000	67,937	69,184	Dec 05 08:45 PM
Barth Jay	Chief Medical Officer	Dec 01	Sale	13.59	5,000	67,937	64,184	Dec 05 08:45 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience